Advertisement
Advertisement
U.S. markets open in 2 hours 30 minutes
Advertisement
Advertisement
Advertisement
Advertisement

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.30-0.42 (-5.44%)
At close: 04:00PM EST
7.29 -0.01 (-0.14%)
Pre-Market: 04:35AM EST
Advertisement
Sign in to post a message.
  • M
    Max
    There are 100 biotech companies trading below net cash.

    https://twitter.com/zavaindar/status/1486089092903362562/photo/1
  • o
    oliver
    Dreaming right now...
    What I would absolutely love here is a tiered BO similar to ZGNX.
    Let's say 12/sh right now upfront - BP is paying ~$400M for tech and assets.
    Then milestone payments for approval of each TDT, CALD, and SCD to shareholders who hold.
    Maybe $0.50/sh for CALD, $3/sh for TDT, and $6/sh for SCD.

    Yes, California Dreaming....
  • o
    oliver
    looks like first trust advisors upped their share count from 2.3M to 5.2M shares.......
  • c
    craig
    Their main phone number is no longer in service lol.
    A BO wont happen. No one woulx even rust what they have filed with the fda.
  • M
    Max
    Not that you can believe anything Bluebird says in a press release, I mean, everything they said in the 1/11 update at JPM turned out not to be true (no Adcom was scheduled and they will not be launching new drugs in "mid-2022"), but regarding their financial situation, they said, "full-year 2022 cash burn is expected to be less than $400 million." Take that with a grain of salt, but that works out to ($33m) per month. So, every quarter the company is worth roughly $1.40 less (($99m)/70m shares).

    January: $7.00 (being generous here)
    April: $5.60
    July: $4.20

    I expect the stock to be around the $4 level when that Adcom rolls around, assuming it ever gets on the schedule unless Andrew does something.

    What is there to do?

    1) Sell the whole company (advisable)
    2) Dilute common shareholders (not advisable but most likely outcome)
    3) Sell the EU rights to CALD and TDT (yeah, right, that and ten euros will get you a cup of coffee and a metro ticket)
  • M
    Max
    https://twitter.com/bradloncar/status/1486344591586516999?s=20

    Worth following Brad. Lots of interesting information and commentary.
  • и
    игорь
    I think that the decision to reschedule the FDA application for eli-cel and beti-cel came as a surprise and a blow to them. They frantically search for money for operations, but in the face of rising inflation and higher rates, they most likely will not find them. This means that they really only have 2 exits or bankruptcy or the sale of the company for next to nothing. The history of bluebird is coming to an end. Realizing that I will not get my money back, but I want the mediocre Nick Leschly to be punished and spend all my money on lawyers
  • M
    Max
    Can't wait to see how low it goes when they announce they have to push back SCD again, again, again, again, again. I've lost track of how many times they've delayed it. Would be an interesting project to track those announcements against the stock collapse.
  • B
    BOB
    Can't we get one of these 2 sold at least we could have some redemption and move on to something of better quality. Just so fearful this Leschly but is going to demolish everything in his path. The guys like a tornado.
  • R
    Rita
    he FDA extended the PDUFA goal dates for beti-cel and eli-cel to allow time to review additional clinical information previously submitted by the company in response to FDA information requests as part of its ongoing reviews. The information was deemed a major amendment. @Max how do you read “major amendment”?
  • M
    Max
    Well, look at that. Our two shytebird stocks are green in a horrible tape. Surely they'll close red. I'm not delusional.
  • B
    BOB
    TSVT has the same phone # as Blue that's a crock unbelievable.
  • B
    BOB
    So when they do another offering the amount of shares it will take to come up with the money they need to fund will dilute this to nothing. They're really getting themselves into a really bad situation.
  • B
    BOB
    The Vol wow. Something on stocktwits about abecma approved for Japan.
  • и
    игорь
    Their financial situation is simply terrible. At the beginning of the year they had approximately $442 million, including restricted cash of approximately $46 million. Judging by their report, they burn an average of 70 million monthly. So, if there is no money coming in, they will go bankrupt in June 2022. That is, they will not live to see PDUFA August 19, 2022 and
    September 16, 2022. As a result, the market value of their shares will become 0. All that can save them is a buyout. But I think the point is not that there are no potential applicants, but that the management has no desire to sell the company.
  • o
    oliver
    Deep green xbi and market not even providing support here.
    Market going to force their hand a lot sooner than later
  • B
    BOB
    Even if blue comes thru in Aug which I don't believe then there in head winds with vrtx. Plus going against a rough and tumble market.
  • o
    oliver
    Developed PTSD with this stock - I cringe every time they PR anything.
    At least it's not a hold; not sure there's anything left to put on hold.
    "not expected to impact the priority review status of either BLA or the potential for bluebird bio to be granted priority review vouchers" - shows how desperate they are; aka we need to be able to sell those PRVs.
  • c
    craig
    There is no buyout or any other saving grace for blue. It's just a ride to bottom. Look at volume yesterday. Even longs are giving up.
  • M
    Max
    VRTX presented at the JP Morgan conference. Reiterated the plan to file BLA/MAA for CTX-001 in SCD and TDT in Q4 2022.

    Meanwhile, BLUE has part of its program on hold and is talking about pushing its SCD filing even further into 2023.
Advertisement
Advertisement